TABLE 2.
Study Characteristics and Cardiac MRI Findings in Case Series With Aggregated‐Level Data
| ID | Author | N | Male/Female | Age (Years) | Type of Vaccine | First/SeconD dose | Time From Vaccine to Symptom (Days) | Cardiac Symptoms and Biomarkers and ECG | Echocardiography Findings | Time From Vaccine to MRI (Day) | Cardiac MRI Findings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Jain et al (2021) | 56 | NR | 12–20 | mRNA (NR) | 0/56 | 0–7 |
Chest pain: 56/56 Elevated troponin: 56/56 |
NR | 4.9 (2.3) a |
Abnormal T2: 50/56 (89%) LGE: 49/56 (88%) Inferolateral or lateral: 49/49 ECV: 32.6 (9) a LLC: 49/56 (88%) LVEF: 58 (6) a Abnormal LVEF: 13/56 (23%) Others: NR |
| 2 | Montogomery et al (2021) | 8 | 8/0 | NR | mRNA (NR) | NR | <4 days |
Elevated troponin: 8/8 Chest pain: 8/8 ECG: NR |
NR | NR |
Abnormal T2: 8/8 (100%) LGE: 8/8 (100%) Subepicardial: 8/8 (100%) LLC: 8/8 (100%) Others: NR |
| 3 | Troung et al (2021) | 97 | NR | Adolescents and young adults | mRNA (Pfizer) | NR | NR | Elevated troponin: 8/8 | NR | 5 (3–17) b |
Abnormal T2: 54/97 (55.4%) LGE: 74/97 (76.3%) LLC: 49/97 (50.5%) LVEF: 60% (55%–62.7%) b Others: NR |
| 4 | Viskin et al (2021) | 7 | 6/1 | 20–34 | mRNA (Pfizer) | 0/7 | 3–7 |
Chest pain: 7/7 Elevated troponin: 7/7 Abnormal ECG: 4/7 Hospitalized: 7/7 |
LVEF < 55%: 2/7 | NR |
Abnormal T2: 1/7 (14%) LGE: 6/7 (86%) Subepicardial: 1/6 (17%) Subepicardial and midwall: 5/6 (83%) LLC: 6/7 (86%) Others: NR |
| 5 | Pfajfer et al (2021) | 3 | 3/0 | 17 [17] a | mRNA (Pfizer) | 2/1 | 1–10 |
Chest pain: 3/3 Elevated troponin: 3/3 Abnormal ECG: 1/3 ST‐Elevation: 0/3 Hospitalized: 3/3 |
LVEF < 55%: 0/3 WMA: 0/3 Pericardial Effusion: 0/3 |
5–10 |
Abnormal T2: 0/3 LGE: 3/3 Subepicardial: 2/3 Midwall: 1/3 LLC: 0/3 Precardial Effusion: 1/3 Abnormal LVEF: 0/3 Others: NR |
| 6 | Lyengar et al (2022) | 3 | NR | 27 | NR | 0/3 | 3 |
Chest pain: 3/3 Elevated troponin: 3/3 Abnormal ECG: 2/3 ST‐Elevation: 2/3 Hospitalized: 3/3 |
LVEF < 55%: 2/3 | 3–5 |
Abnormal T2: 3/3 (100%) LGE: 3/3 (100%) Subepicardial: 2/3 (66%) Subepicardial and Midwall: (33%) LLC:NR Others: NR |
ECV = extracellular volume; ECG = electrocardiography; LGE = late gadolinium enhancement; LLC = Lake Louise criteria; LVEF = left ventricular ejection fraction; mRNA = messenger ribonucleic acid; NR = not reported; WMA = wall motion abnormality.
Mean (standard deviation).
Median (inter quartile range).